[Corrigendum] Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma

Koh-Ichi Nakashiro1, Hiroshi Tanaka1, Hiroyuki Goda1

  • 1Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Toon, Ehime 791-0295, Japan.

PubMed

Insights

A scientific corrigendum clarifies an error in figure assembly for western blots in a published study. The authors confirm the error did not significantly impact the study's conclusions.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology Research

Context:

  • A previously published study in International Journal of Oncology faced scrutiny regarding western blot figures.
  • A reader identified potential similarities and discrepancies between control beta-tubulin blots in Fig. 1C and Fig. 3A.

Purpose:

  • To address and correct an inadvertent error in the assembly of Fig. 3.
  • To provide a revised figure (Fig. 3) with accurate representation of Akt1 and beta-tubulin blots.
  • To maintain scientific integrity and transparency.

Summary:

  • The authors identified an error where Fig. 3 was assembled incorrectly, leading to a visual similarity between beta-tubulin blots from different figures.
  • A corrected Fig. 3 is presented, displaying data from repeated experiments for both Akt1 and beta-tubulin.
  • The authors verified that this assembly error did not substantially alter the original study's conclusions.

Impact:

  • Ensures accuracy of published scientific data, specifically western blot representations.
  • Upholds the credibility of the research findings by correcting procedural errors.
  • Provides clarity to readers and the scientific community regarding the western blot data.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K